EUCTR2007-004225-26-IT进行中（未招募）不适用
A multicenter, randomised, double-blind, double-dummy, phase III study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) each administered with a background regimen in HIV-1 infected, antiretroviral treatment-experienced adults. - ND
Gilead Sciences Incorporated0 个研究点目标入组 700 人开始时间: 2008年7月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •. Plasma HIV-1 RNA levels > or = 1000 copies/ml at screening . Documented viral resistance or at least six months experienced prior to screening with two or more different classes of antiretroviral agents. . Stable current antiretroviral regimen for at least 30 days prior to screening . No prior treatment with any HIV-1 integrase inhibitor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •. A new AIDS-defining condition diagnosed within the 30 days prior to screening . Prior treatment with any HIV-1 integrase inhibitor . Subjects experiencing ascites or encephalopathy . Females who are breastfeeding . Positive serum pregnancy at any time during the study
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-NLBayer HealthCare AG5,890
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioSubjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or bothMedDRA version: 18.1Level: LLTClassification code 10076410Term: Chronic kidney disease stage 3System Organ Class: 100000004857MedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10066498Term: Cardiac failure chronic aggravatedSystem Organ Class: 100000004849MedDRA version: 18.1Level: LLTClassification code 10076408Term: Chronic kidney disease stage 1System Organ Class: 100000004857MedDRA version: 18.1Level: LLTClassification code 10076409Term: Chronic kidney disease stage 2System Organ Class: 100000004857EUCTR2015-002168-17-ESBayer HealthCare AG5,890
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-HUBayer HealthCare AG5,890
进行中（未招募）
不适用
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and placebo in patients with type 2 diabetesmellitus inadequately controlled with metformin. - EMERGE 4Type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2008-001854-42-DEF.Hoffmann-La Roche Ltd630
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-FIBayer HealthCare AG5,890